1
George Stuart Cockerill, Malcolm Clive Carter, Stephen Barry Guntrip, Kathryn Jane Smith: Fused heterocyclic compounds as protein tyrosine kinase inhibitors. SmithKline Beecham Corporation, John L Lemanowicz, May 21, 2002: US06391874 (80 worldwide citation)

Substituted heteroaromatic compounds of formula (I) and in particular substituted quinolines and quinazolines, are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for ...


2

3

4
George Stuart Cockerill, Malcolm Clive Carter, Stephen Barry Guntrip, Kathryn Jane Smith: Protein tyrosine kinase inhibitors. SmithKline Beecham Corporation, John L Lemanowicz, April 20, 2004: US06723726 (43 worldwide citation)

Substituted heteroaromatic compounds, and in particular substituted bicyclic heteroaromatic compounds of formula (I), wherein X is N or CH; A represents a fused 5, 6 or 7-membered heterocyclic ring containing 1 to 5 heteroatoms which may be the same or different and which are selected from N, O or S ...


5
George Stuart Cockerill, Malcolm Clive Carter, Stephen Barry Guntrip, Kathryn Jane Smith: Heterocyclic compounds. SmithKline Beecham Corporation, John L Lemanowicz, December 7, 2004: US06828320 (40 worldwide citation)

Substituted heteroaromatic compounds, and in particular substituted quinolines and quinazolines, are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in th ...


6
George Stuart Cockerill, Malcolm Clive Carter, Stephen Barry Guntrip, Kathryn Jane Smith: Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors. Glaxo Wellcome, John L Lemanowicz, January 16, 2001: US06174889 (38 worldwide citation)

Substituted heteroaromatic compounds, and in particular substituted bicyclic heteroaromatic compounds of formula (I), wherein X is N or CH; A represents a fused 5, 6 or 7-membered heterocyclic ring containing 1 to 5 heteroatoms which may be the same or different and which are selected from N, O or S ...


7
Malcolm Clive Carter, George Stuart Cockerill, Stephen Barry Guntrip, Karen Elizabeth Lackey, Kathryn Jane Smith: Heterocyclic compounds. SmithKline Beecham Corporation, John L Lemanowicz, March 30, 2004: US06713485 (34 worldwide citation)

The present invention relates to substituted heteroaromatic compounds, methods for their preparation, pharmaceutical compositions containing them and their use in medicine. Specifically, the invention relates to quinazoline derivatives useful in treating disorders mediated by protein tyrosine kinase ...


8
George Stuart Cockerill, Malcolm Clive Carter, Stephen Barry Guntrip, Kathryn Jane Smith: Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors. Glaxo Wellcome, John L Lemanowicz, March 27, 2001: US06207669 (33 worldwide citation)

Substituted heteroaromatic compounds, and in particular substituted bicyclic heteroaromatic compounds in which one ring is a pyridine or pyrimidine of formula (I) are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions inc ...


9
Richard Martyn Angell, Nicola Mary Aston, Paul Bamborough, George Stuart Cockerill, Suzanne Joy Merrick, Kathryn Jane Smith, Ann Louise Walker: 5′-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors. Glaxo Group, Dara L Dinner, Stephen Venetianer, Charles M Kinzig, April 24, 2007: US07208629 (10 worldwide citation)

Compounds of formula (I): wherein when m is 0 to 4 R1 is selected from C1–6alkyl, C3–7cycloalkyl, C2–6alkenyl, —SO2NR4R5, —CONR4R5 and —COOR4; and when m is 2 to 4 R1 is additionally selected from C1–6alkoxy, hydroxy, NR4R5, —NR4SO2R5, —NR4SOR5, —NR4COR5, and —NR4CONR4R5; R2 is selected from hydroge ...


10